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Abstract
The Lapinized Philippines Coronel (LPC) vaccine, an attenuated strain of classical swine fever virus (CSFV), is an
important tool for the prevention and control of CSFV infection and is widely and routinely used in most CSF
endemic areas, including Taiwan. The aim of this study was to investigate whether PCV2 infection affects the
efficacy of the LPC vaccine. Eighteen 6-week-old, cesarean-derived and colostrum-deprived (CDCD), crossbred pigs
were randomly assigned to four groups. A total of 10
5.3 TCID50 of PCV2 was experimentally inoculated into pigs
through both intranasal and intramuscular routes at 0 days post-inoculation (dpi) followed by LPC vaccination 12
days later. All the animals were challenged with wild-type CSFV (ALD stain) at 27 dpi and euthanized at 45 dpi.
Following CSFV challenge, the LPC-vaccinated pigs pre-inoculated with PCV2 showed transient fever, viremia, and
viral shedding in the saliva and feces. The number of IgM
+, CD4
+CD8
-CD25
+, CD4
+CD8
+CD25
+, and CD4
-CD8
+CD25
+ lymphocyte subsets and the level of neutralizing antibodies against CSFV were significantly higher in the animals
with LPC vaccination alone than in the pigs with PCV2 inoculation/LPC vaccination. In addition, PCV2-derived
inhibition of the CSFV-specific cell proliferative response of peripheral blood mononuclear cells (PBMCs) was
demonstrated in an ex vivo experiment. These findings indicate that PCV2 infection decreases the efficacy of the
LPC vaccine. This PCV2-derived interference may not only allow the invasion of wild-type CSFV in pig farms but
also increases the difficulty of CSF prevention and control in CSF endemic areas.
Introduction
Classical swine fever virus (CSFV) is an enveloped, posi-
tive sense, and single stranded RNA virus belonging to
the genus Pestivirus within the family Flaviviridiae [1,2].
This virus causes systemic hemorrhage in domestic pigs
and leads to severe economic losses in the swine indus-
try worldwide. Currently, classical swine fever (CSF) is
still rampant in most Asian and Latin American and in
some European countries [1].
In most endemic areas, such as Taiwan, Lapinized
Philippines Coronel (LPC) vaccine, an attenuated CSFV
strain, is an important tool for prevention and control
of CSF. The LPC is attenuated from a virulent CSFV
strain by several hundred passages in the rabbit and is
used as a modified live CSFV vaccine [3]. The LPC vac-
cine is able to induce complete protection in pigs
against virulent CSFV challenge, and LPC-vaccinated
pigs do not show any clinical signs, viremia or shedding
of CSFV [4,5].
Porcine circovirus type 2 (PCV2) is distributed world-
wide and has been suggested as a major causative agent
of postweaning multisystemic wasting syndrome
(PMWS) in pigs [6,7]. The characteristics of clinical and
immunological pathology in PMWS-affected pigs are
lymphocyte depletion, increase in population of mono-
cyte/macrophage lineage cells in lymphoid tissues and
peripheral blood, and irregular cytokine responses con-
stitutionally or after stimulation [7,8]. It is known that
PCV2 infection decreases the protection efficacy of
modified porcine reproductive and respiratory syndrome
virus (PRRSV) vaccine [9]. In addition, PCV2 infection
could immunomodulate the pseudorabies virus (PRV)
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any medium, provided the original work is properly cited.recall antigen responses in pigs, either by viral compo-
nents or through soluble factors like IL-10 [10,11].
Therefore, the aim of this study was to investigate
whether PCV2 infection could decrease or interfere with
the efficacy of LPC vaccine.
PMWS primarily occurs in pigs between 25 and 120
days of age, with high prevalence between 60 and 80 days
of age [7]. Unfortunately, the susceptible age of PCV2
infection in pigs overlaps with the age of LPC vaccina-
tion, which is around the postweaning stage in the man-
agement of the pig farm [4,7]. This situation highlights
the importance of this study in the area using LPC vac-
cine to control CSF. In the present study, experimentally
PCV2-infected and LPC-vaccinated cesarean-derived,
colostrum-deprived (CDCD) piglets were challenged with
wild-type CSFV. Clinical signs, viremia, viral shedding,
change in lymphocyte subpopulations, as well as humoral
and cell-mediated immune (CMI) responses were evalu-
ated. It was revealed that PCV2 infection could decrease
the efficacy of LPC vaccine and the mechanisms of the
immune interference were also demonstrated.
Materials and methods
Virus and cells
A PCV1-free porcine kidney cell line (PK-15) was used
to propagate PCV2 and CSFV (ALD strain) [12]. The
PCV2 was isolated from a PMWS-affected pig and it
was PCV2b in its genotype by sequencing. The ALD is a
high virulent strain of CSFV isolated from Japan that it
has been demonstrated to cause severe clinical signs and
lesions in infected pigs [12] and is a challenged strain
for evaluating the efficacy of LPC vaccine in Taiwan.
The viral titers of PCV2 and the ALD strain of CSFV
were determined to be 10
5.0 and 10
6.8 TCID50 per mL,
respectively, by virus titration [1].
Experimental animals
The animal experiments performed in the present study
were all approved by the Institutional Animal Care and
Use Committee of Animal Health Research Institute
(98013) under the guidelines of the Animal Protection
Act in Taiwan. Eighteen 6-week-old, crossbred CDCD
pigs were randomly divided into four groups and housed
in four separated biocontainment animal rooms at the
Animal Health Research Institute as shown in Table 1.
The pigs in groups 1 and 2 were intranasally inoculated
with 0.5 mL of PCV2 in each nostril and were intramus-
cularly injected with 1 mL of PCV2 at the right side of
the dorsal neck region at 0 dpi (a total dose of 10
5.3
TCID50 per pig). The pigs in groups 1 and 3 were intra-
muscularly injected with 1 dose of LPC vaccine/pig at
the right side of the dorsal neck region at 12 dpi. Due
to that pigs obtained complete protection against
virulent CSFV challenge as early as 1 week after LPC
vaccination and the neutralizing antibodies in LPC-vac-
cinated pigs were detectable at 2-3 post-vaccination
weeks [4], a 15-day-duration between vaccination and
challenge was selected as a proper time frame to see the
interference of vaccine efficacy by PCV2 infection.
Therefore, all pigs were challenged with 1 mL of CSFV
(ALD strain)/pig by intramuscular injection at the left
side of the dorsal neck region at 27 dpi (a total dose of
10
6.8 TCID50 per pig). Clinical monitoring was recorded
daily, and rectal temperature and sample collection of
blood, saliva, and feces were taken every 3 days until 45
dpi. All surviving pigs were necropsed at 45 dpi.
Detection of PCV2 and CSFV viremia and shedding
PCV2 and CSFV in plasma, saliva, and feces were
detected by real-time PCR (rPCR) or reverse transcrip-
tion real time PCR (rRT-PCR), respectively. Total
nuclear acid of plasma, saliva, and feces was extracted
by MegNA Pure LC Total Nucleic Acid Isolation kit
according to the manufacturer’s instructions (Roche,
Mannheim, Germany). Universal-PCV primers which
were the common primers for PCV1, PCV2a, and
PCV2b and specific-PCV2 TaqMan probe were used in
rPCR for PCV2 detection. The primer and probe
sequences were 5’-GCTGGCTGAACTTTTGAAA-3’,
5’-CCTTTAGTCTCTACAGTCAATGGAT-3’,a n d
5’-FAM-TGCTAATTTTGCAGACCCGGAAACCAC-
BHQ1-3’. The rPCR of PCV2 was carried out in the
LightCycler
® 480 system (Roche, Mannheim, Germany)
in a reaction volume of 20 μL, containing 5 μLo fD N A ,
1× LightCycler
® TaqMan
® Master (Roche, Mannheim,
Germany), 0.15 μMP C V 2T a q M a np r o b e ,a n d0 . 5μM
of each universal-PCV primer. The reaction condition
involved initial incubation at 95°C for 10 min followed
by 45 cycles of denaturation (95°C for 20 s), annealing
(60°C for 30 s), and extension (72°C for 20 s). The rRT-
PCR for CSFV detection was the same as that described
by Huang et al. [1].
Table 1 Experimental design
a.
Group number Pig number PCV2 LPC CSFV
Group 1 6 + + +
Group 2 6 + - +
Group 3 3 - + +
Group 4 3 - - +
PCV2: Porcine circovirus type 2; LPC: Lapinized Philippines Coronel; CSFV:
Classical swine fever virus.
Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-
infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and
group 4: CSFV-challenged.
aThe pigs were inoculated with 10
5.3 TCID50 of PCV2 (group 1 and 2), 1 dose
of LPC vaccine (group 1 and 3), and 10
6.8 TCID50 of wild-type CSFV (ALD)
(group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively.
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peripheral blood
The total number of lymphocytes in peripheral blood
was counted by MS4-PACK
® kit according to the man-
ufacturer’s instructions (Melet Schloesing Laboratories,
Osny, France) and they were further divided into IgM
+,
CD4
-CD8
+CD25
+,C D 4
+CD8
-CD25
+,a n dC D 4
+CD8
+CD25
+ subgroups by flow cytometry using monoclonal
antibodies (mAbs) against IgM, CD4, CD8, and CD25
surface antigens on porcine lymphocytes. Briefly, lym-
phocytes were isolated by the Uti-Lyse kit according to
the manufacturer’s instructions (Dakocytomation,
Carpinteria, CA, USA) and were divided into the IgM
subgroup and the CD4CD8CD25 subgroup. The lym-
phocytes in the IgM subgroup were stained with mouse
anti-pig IgM mAb (AbD Serotec, Kidlington, UK), fol-
lowed by FITC-conjugated rat anti-mouse IgG1 mAb
(AbD Serotec, Kidlington, UK). The lymphocytes in the
CD4CD8CD25 subgroup were stained with FITC-conju-
gated mouse anti-pig CD4 mAb, PE-conjugated mouse
a n t i - p i gC D 8m A b( B DB i o s c i e n c e s ,S u n n y v a l e ,C A ,
USA), and mouse anti-pig CD25 mAb (AbD Serotec,
Kidlington, UK), followed by PerCP-conjugated rat anti-
mouse IgG1 mAb (BD Biosciences, Sunnyvale, CA,
USA), which can link mouse anti-pig CD25 mAb.
Finally, lymphocytes in each sample were gated and ana-
lyzed by CellQuest software from FACSCalibur cytome-
try (BD Biosciences, Sunnyvale, CA, USA). The absolute
number of each subgroup was calculated as follows:
absolute number = total lymphocytes × percentage of
positive cells on lymphocyte gate.
Detection of PCV2 antibody and CSFVneutralizing
antibody
PCV2 antibody in serum was detected by SERELISA
PCV2 Ab Mono Blocking kit according to the manufac-
turer’s instructions (Synbiotics Europe SAS, Lyon Cedex,
France). The neutralizing antibody of CSFV in serum
was detected using the OIE protocol [2].
Ex vivo CSFV-specific cell proliferative response of PBMCs
To understand how the immunomodulation of PCV2
infection affecting the efficacy of LPC vaccine, an ex
vivo CSFV-specific cell proliferative response of PBMCs
was performed. Because the CSFV-specific cell prolifera-
tive response of PBMCs can only be detected in pigs 30
days after virulent CSFV infection [13], another animal
experiment was established to perform this assay.
Briefly, five 4-week-old, non-vaccinated, healthy, con-
ventional piglets were obtained from a commercial herd
without the history of specific swine diseases, including
CSF, PRRS, swine influenza, and pseudorabies. The pig-
lets were negative in antibody and nuclear acid detection
of the four viral pathogens mentioned above by RT-PCR
or PCR and commercial ELISA kits, but PCV2 was
detected by rPCR with the amount of 10
1.2 to 10
3.3
copies of PCV2 genome per 10
6 PBMCs. The piglets
were housed in a biocontainment animal house at the
Animal Health Research Institute, where they were vac-
cinated with LPC vaccine at the right side of the dorsal
neck region at 4 and 7 weeks of age and inoculated with
1 mL of CSFV (ALD strain)/pig by intramuscular injec-
tion at the left side of the dorsal neck region at 9 weeks
o fa g e( at o t a ld o s eo f1 0
6.8 TCID50 per pig). Each pig
was bled at 15-17 weeks of age and K3EDTA (Sigma-
Aldrich, St. Louis, MO, USA) was used to prevent coa-
gulation. The animal experiments performed in the pre-
sent study were all approved by the Institutional Animal
Care and Use Committee of Animal Health Research
Institute (97013) under the guidelines of the Animal
Protection Act in Taiwan.
PBMCs were isolated from 8 mL of anti-coagulated
blood with K3EDTA by centrifugation at 400 × g on
Histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA).
PBMCs at 10
6 cells/mL were cultured in RPMI-1640
(Invitrogen, Carlsbad, CA, USA) containing 10% (vol/
vol) heat-inactivated fetal bovine serum, 100 units/mL
penicillin G, 100 μg/mL streptomycin, and 0.25 μg/mL
amphotericin B. All of the fetal bovine serum used in
the present study tested negative for pestivirus by RT-
PCR and anti-pestivirus antibodies by IFA.
To evaluate whether PCV2 has an effect on the CSFV-
specific cell proliferative response of PBMCs, the 96-well
plates with seeded PBMCs at 10
5 cells/well were classi-
fied into a mock group, ALD group, PCV2-0.1/ALD
group, PCV2-0.05/ALD group, PCV2-0.01/ALD group,
UV-inactivated PCV2-0.1/ALD, and Con A group.
PCV2 at 0.1, 0.05, and 0.01 MOI and 0.1 MOI of UV-
inactivated PCV2 were separately added into PBMCs of
each group 18 h before stimulation with 1 MOI of ALD.
Concanavalin A at 5 μg/mL (Sigma-Aldrich, St. Louis,
MO, USA) was added into the Con A group as the con-
trol. Following CSFV or Con A stimulation, the prolif-
erative responses of PBMCs were measured by cell
proliferation ELISA kit (Roche, Mannheim, Germany) at
4 days post-stimulation (dps). The kit detects bromo-
deoxyuridine (BrdU) incorporation during DNA synth-
esis in proliferating cells. The assay procedure for
PBMC proliferative response was performed according
to the manufacturer’s instructions.
Statistical analysis
The ratio of feverish, viremia, and viral shedding ani-
mals was analyzed by the Fisher Exact Probability test.
Comparisons of the values between two groups and
among various groups were analyzed by the Student’s t-
test and one-way analysis of variance (ANOVA), respec-
tively. ANOVA was combined with the Duncan multiple
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out by statistical analysis system (Statistical Analysis
System; SAS for Windows 6.12; SAS Institute Inc., Cary,
NC, USA). A P value of less than 0.05 was considered
to be statistically significant.
Results
PCV2 infection caused transient fever and clinical signs in
LPC-vaccinated animals after CSFV challenge
Clinically, all of the pigs with LPC vaccination (group 1
and group 3) survived and the majority of pigs in both
groups showed no fever or clinical syndromes such as
depression, anorexia, and cyanosis. Transient fever (>
40.5°C) was noted in one of the animals previously
inoculated with PCV2 (group 1) during the 6
th to 12
th
day after challenge (Table 2). Although no statistical sig-
nificant difference in the number of the feverish animals
in both groups was noted, the duration of fever in
group 1 (1.5 ± 1.5 days) was significantly longer than
that of group 3 (0 ± 0 days) and the average rectal tem-
perature in group 1 was significantly higher than that of
group 3 from the 3
rd to the 9
th day after wild-type
CSFV challenge. In the pigs without LPC vaccination, all
animals showed clinical signs and fever. The animals
started to die at the 12
th day after challenge and all the
pigs died at the 16
th day post challenge. Compared to
t h es i m p l eC S F Vi n f e c t i o n( g r o u p4 ) ,t h ea v e r a g es u r v i -
val days of pre-infection with PCV2 and then a chal-
lenge with wild-type CSFV (group 2) were significantly
shorter than that of group 4 (13.8 ± 1.3 vs. 15.7 ± 0.5
days).
PCV2 infection caused transient wild-type CSFV viremia
and viral shedding in saliva and feces in LPC-vaccinated
animals after CSFV challenge
Viremia and viral shedding of the challenged wild-type
virus in the vaccinated animals were important factors
by which to evaluate the efficacy of vaccination. In this
study, no viremia and viral shedding of wild-type CSFV
were noted in the experimental animals with LPC vacci-
nation alone (group 3) (Tables 3, 4, and 5). Transient
viremia and viral shedding of wild-type CSFV in the sal-
iva and feces were noted in the animals previously
infected with PCV2 (group 1). The viremia first
appeared at the 3
rd day after challenge and could last up
to the 15
th day post-challenge (Table 3). The appearance
of viral shedding in the saliva was slower and the dura-
tion was shorter, which could only be detected at 9 to
12 days post-challenge (Table 4). Fecal viral shedding
had a similar pattern and was also detected only
between the 9
th and 15
th d a yp o s t - c h a l l e n g e( T a b l e5 ) .
Following wild-type CSFV challenge, there were only
one to three out of 6 pigs in group 1 developing viremia
or viral shedding (Tables 3, 4, and 5). Although no sta-
tistical significant difference in the number of the vire-
mia and shedding animals of wild-type CSFV in both
groups was noted, the duration of viremia (3.5 ± 3.6
Table 2 Changes in the number of pigs developing fever
in various treatment groups over time after classical
swine fever virus (CSFV) challenge
a.
dpi 27 30 33 36 39 42 45
Group 1 0/6
b 0/6 1/6 1/6 1/6 0/6 0/6
Group 2 0/6 6/6 3/6 4/6 3/4 0/1 0/0
Group 3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Group 4 0/3 1/3 2/3 2/3 2/3 1/3 0/0
Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-
infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and
group 4: CSFV-challenged.
aThe pigs were inoculated with 10
5.3 TCID50 of PCV2 (group 1 and 2), 1 dose
of LPC vaccine (group 1 and 3), and 10
6.8 TCID50 of wild-type CSFV (ALD)
(group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively.
bNumber of animals with fever/number of surviving animals.
Table 3 Changes in the number of pigs developing
porcine circovirus type 2 (PCV2) and wild-type classical
swine fever virus (CSFV) viremia in various treatment
groups over time after CSFV challenge
a.
dpi 27 30 33 36 39 42 45
Group 1 6/0/6
b 6/3/6 6/2/6 6/1/6 6/1/6 6/1/6 6/0/6
Group 2 6/0/6 6/6/6 6/6/6 6/6/6 4/4/4 1/1/1 0/0/0
Group 3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3
Group 4 0/0/3 0/3/3 0/3/3 0/3/3 0/3/3 0/3/3 0/0/0
Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-
infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and
group 4: CSFV-challenged.
aThe pigs were inoculated with 10
5.3 TCID50 of PCV2 (group 1 and 2), 1 dose
of LPC vaccine (group 1 and 3), and 10
6.8 TCID50 of wild-type CSFV (ALD)
(group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively. The PCV2 and wild-
type CSFV loads in plasma were detected by real-time PCR or reverse
transcription real-time PCR, respectively.
bNumber of PCV2-positive animals/number of wild-type CSFV-positive
animals/number of surviving animals.
Table 4 Changes in the number of pigs showing viral
shedding of porcine circovirus type 2 (PCV2) and wild-
type classical swine fever virus (CSFV) in the saliva of
various treatment group over time after CSFV challenge
a.
dpi 27 30 33 36 39 42 45
Group 1 6/0/6
b 4/0/6 4/0/6 5/2/6 6/2/6 6/0/6 3/0/6
Group 2 6/0/6 5/0/6 5/1/6 5/4/6 4/4/4 1/1/1 0/0/0
Group 3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3
Group 4 0/0/3 0/0/3 0/0/3 0/0/3 0/2/3 0/2/3 0/0/0
Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-
infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and
group 4: CSFV-challenged.
aThe pigs were inoculated with 10
5.3 TCID50 of PCV2 (group 1 and 2), 1 dose
of LPC vaccine (group 1 and 3), and 10
6.8 TCID50 of wild-type CSFV (ALD)
(group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively. The PCV2 and wild-
type CSFV loads in saliva were detected by real-time PCR or reverse
transcription real-time PCR, respectively.
bNumber of PCV2-positive animals/number of wild-type CSFV-positive
animals/number of surviving animals.
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1.7 days in feces) in group 1 was significantly longer
than that of group 3 (0 ± 0 days in viremia, saliva, and
feces). In the wild-type CSFV-challenged animals with-
out LPC vaccination of groups 2 and 4, viremia and
viral shedding could be detected more profoundly
(Tables 3, 4, and 5). Viremia and viral shedding of
PCV2 were detected in the two PCV2-inoculated groups
and groups 1 and 2; however, there were no significant
differences regarding the frequency and duration
between the two groups (Tables 3, 4, and 5).
PCV2 infection decreased the levels of lymphocyte
subgroups in LPC-vaccinated animals after CSFV
challenge
In order to understand how PCV2 affected the efficacy
of LPC vaccine after wild-type CSFV challenge, changes
in lymphocyte subsets among different groups were
compared. Lymphocytes are classified by surface mole-
cules of IgM, CD4, and CD8 into B-lymphocytes, T-
helper lymphocytes, and cytotoxic T lymphocytes,
respectively, and CD25 expression on lymphocytes is
associated with the level of activation [14,15]. Thus, the
populations of lymphocyte subsets of IgM
+,C D 4
+CD8
-
CD25
+,C D 4
+CD8
+CD25
+,a n dC D 4
-CD8
+CD25
+ were
measured in the present study. Although there was a
transient change in the level of IgM
+, CD4
+CD8
-CD25
+,
CD4
+CD8
+CD25
+,a n dC D 4
-CD8
+CD25
+ lymphocyte
subsets after PCV2 infection and LPC vaccination (data
not shown), a profound pattern of statistical difference
between groups 1 and 3 was clear after wild-type CSFV
challenge (Figure 1). PCV2 pre-infection could signifi-
cantly decrease the cell proliferation of the four subsets
stimulated by CSFV challenge. The numbers of IgM
+,
CD4
+CD8
-CD25
+,C D 4
+CD8
+CD25
+,a n dC D 4
-CD8
+CD25
+ lymphocyte subsets in group 1 were signifi-
cantly lower than that of group 3 at 30-42 dpi, 30-42
dpi, 30-33 dpi, and 30-39 dpi, respectively. In the groups
without LPC vaccination, the cells of all four subsets
eventually gradually decreased over time after wild-type
CSFV challenge and became undetectable at the end of
the experiment.
PCV2 infection caused transient delay of CSFV
neutralizing antibody development
Based on the data, it is clear that PCV2 infection could
result in an incomplete protection of LPC vaccine
against wild-type CSFV challenge. Clinical signs, viremia,
and viral shedding were observed in some of the LPC-
vaccinated animals that were previously inoculated with
PCV2. Compared to the group with LPC-vaccination
alone, the lymphocyte subset related to antibody produ-
cing cells (IgM
+) was also significantly decreased in the
PCV2-infected and LPC-vaccinated group (Figure 1). In
order to see if the decreased level in IgM
+ lymphocyte
subgroup was correlated with the level of antibody pro-
duction, the level of neutralizing antibody against CSFV
was evaluated. In the group with LPC vaccination alone,
the CSFV neutralizing antibody was detectable on the
15
th day after LPC vaccination and the level continu-
ously increased after CSFV challenge till the end of the
study. However, pre-infection of PCV2 delayed the
onset of CSFV neutralizing antibody production (Figure
2), but the antibody level elevated after CSFV challenge
and eventually reached a level similar to that of the sim-
p l eL P Cv a c c i n a t i o ng r o u p( g r o u p3 )a tt h ee n do ft h e
study. The result indicates that PCV2 infection could
transiently block the LPC vaccination-induced neutraliz-
ing antibody production. The anti-PCV2 antibody was
only detected in PCV2-inoculated pigs (groups 1 and 2)
between 15 and 45 dpi, and their levels were not signifi-
cantly different (data not shown).
PCV2 infection suppressed the development of CSFV-
specific cell proliferative response
T h eC M Ii sav e r yi m p o r t a n td e f e n s i v es y s t e ma g a i n s t
CSFV infection, especially in the initial infection stage,
when the neutralizing antibody is undetectable in the
infected pigs [4,5]. In the present study, an ex vivo
CSFV-specific cell proliferation experiment using
PBMCs was performed to investigate whether PCV2
infection would interfere with the development of CMI
against CSFV infection. A clear and significant CSFV-
specific cell proliferation of PBMCs could be demon-
strated four days after stimulation by the ALD strain of
CSFV. However, the presence of PCV2 significantly
reduced the cell proliferation response to the level as
the mock control (Figure 3). The levels of PCV2-derived
reduction among various doses of PCV2 were not
Table 5 Changes in the number of pigs showing viral
shedding of porcine circovirus type 2 (PCV2) and wild-
type classical swine fever virus (CSFV) in the feces of
various treatment groups over time after CSFV
challenge
a.
dpi 27 30 33 36 39 42 45
Group 1 6/0/6
b 6/0/6 6/0/6 6/2/6 6/3/6 6/1/6 6/0/6
Group 2 6/0/6 6/0/6 6/1/6 6/4/6 4/4/4 1/1/1 0/0/0
Group 3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3
Group 4 0/0/3 0/0/3 0/3/3 0/1/3 0/1/3 0/1/3 0/0/0
Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-
infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and
group 4: CSFV-challenged.
aThe pigs were inoculated with 10
5.3 TCID50 of PCV2 (group 1 and 2), 1 dose
of LPC vaccine (group 1 and 3), and 10
6.8 TCID50 of wild-type CSFV (ALD)
(group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively. The PCV2 and wild-
type CSFV loads in fecal samples were detected by real-time PCR or reverse
transcription real-time PCR, respectively.
bNumber of PCV2-positive animals/number of wild-type CSFV-positive
animals/number of surviving animals.
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PCV2 could also retain the inhibitory effect as the infec-
tious virus did.
Discussion
The present study clearly demonstrates that pre-existing
PCV2 infection may affect the efficacy of LPC vaccine
against wild-type CSFV infection. Without the pre-exist-
ing PCV2 infection, simple LPC vaccination could pro-
vide the pigs full protection from wild-type CSFV
challenge with no fever and other clinical signs, viremia,
a n dv i r a ls h e d d i n g( T a b l e s2 ,3 ,4 ,a n d5 ) .H o w e v e r ,
fever/clinical signs and transient viremia/viral shedding
in saliva and feces could be noted in some and a major-
ity of the pigs, respectively, pre-infected with PCV2 and
then challenged with wild-type CSFV after LPC vaccina-
tion. These results indicate that the efficacy of LPC vac-
cine could be reduced by the presence of PCV2
infection. Clinically, the decreased efficacy of LPC
vaccine may not cause any direct effect on the pigs;
however, it may result in a shortcoming in the immune
defensive system of the herd, which could allow the
invasion of wild-type CSFV into the farm. The dissemi-
nation of the wild-type CSFV on the farm may induce
latent infection or outbreak, depending on the status of
the immunity in each herd. The decreased efficacy of
the attenuated PRRSV vaccine by PCV2 has been docu-
mented [9]. PCV2 infection could interfere with the
immune response against PRV, and the mechanism of
this interference has also been investigated [10,11].
Nevertheless, information on the interaction between
PCV2 and LPC vaccine is very limited. The results of
the present study reveal a reduced efficacy of the LPC
vaccine in the presence of PCV2. This information is
important, especially in the area using attenuated vac-
cine to prevent and control CSFV.
The mechanism of reduced efficacy of LPC vaccine by
PCV2 may correlate with the interference of activation
Figure 1 Changes in the absolute number of IgM
+ (A), CD4
-CD8
+CD25
+ (B), CD4
+CD8
-CD25
+ (C), and CD4
+CD8
+CD25
+ (D) lymphocyte
subsets in various treatment groups of pigs after classical swine fever virus (CSFV) challenged over time as determined by flow
cytometry. The pigs in group 1 (PCV2-infected/LPC-vaccinated/CSFV-challenged) and group 2 (PCV2-infected/CSFV-challenged) were inoculated
with porcine circovirus type 2 (PCV2) at 0 dpi. The pigs in group 1 and group 3 (LPC-vaccinated/CSFV-challenged) were vaccinated with
1 dose of Lapinized Philippines Coronel (LPC) vaccine at 12 dpi. The pigs in all four groups were inoculated with wild-type CSFV (ALD strain) at
27 dpi. Data are shown as mean ± SD.
a-dValues with different superscripts indicate that the differences among groups are statistically significant
(P < 0.05).
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include IgM
+,C D 4
+,C D 8
+,a n dC D 4
+CD8
+ cells. These
lymphocyte subgroups in pigs pre-infected with PCV2
and then challenged with CSFV after LPC vaccination
(group 1) were significantly lower than those in pigs
with LPC vaccination alone (group 3) (Figure 1). This
PCV2-derived interference with lymphoycte activation
reduced the activation of humoral immunity and CMI,
and also correlated with the transiently delayed produc-
tion of neutralizing antibody against CSFV and the
inhibited CSFV-specific cell proliferation of PBMCs
(Figures 2 and 3). According to previous studies, PCV2
may affect PRV recall antigen immune response through
a soluble factor like IL-10 or structure component like
CpG motif [10,11]. Attempts to investigate whether
PCV2-derived inhibition in LPC vaccine-induced
immune response is related to those soluble factors or
components have also been carried out. The results
showed that the CpG motif of PCV2 genome did not
inhibit the CSFV-specific proliferation of PBMCs (data
not shown). In addition, the levels of IL-10 in the
plasma collected from the experimental animals and in
the supernatant of the ex vivo CSFV-specific PBMC
proliferation assay were not significantly different
among various groups (data not shown). The data sug-
gest that the mechanism of PCV2 interfering with the
LPC vaccine-induced immune response may be different
from how PCV2 affects the immune response induced
by PRV. The interaction of PCV2 and the LPC strain of
CSFV is worthy of further study.
Interestingly, although the LPC vaccine-induced
immune response could be disturbed by PCV2, the level
of antibody against PCV2 did not change after LPC vac-
cination or CSFV challenge. This result suggests that
the deregulated immune response in the experimental
animals is antigen-specific. The cell tropism of PCV2
and CSFV is overlapping, which includes monocyte-
macrophage lineage cells and dendritic cells [7,16-19].
Although the impacts of PCV2 and CSFV on dendritic
cells are different [16,19], the age of pig susceptible to
the two viral infections is similar. Therefore, elucidation
of the interaction between PCV2 and CSFV is very
important in the control and prevention of both viral
diseases.
The efficacy of all attenuated CSFV vaccines is corre-
lated with the levels of humoral immunity and CMI
induced by vaccination [4,5]. CMI is important when
neutralizing antibodies are absent in pigs at the early
stage of LPC vaccination [4,5]. The parameters of
CSFV-specific CMI described in the literature, including
interferon-gamma (IFN-g) secretion cells, cell prolifera-
tive activity, and cytotoxicity of lymphocytes, were all
correlated with the protection against CSFV infection
[13,20,21]. In our study, CSFV-specific cell proliferation
Figure 2 The effect of porcine circovirus type 2 (PCV2) on the
development of anti-classical swine fever virus (CSFV)
neutralizing antibody in various treatment groups of pigs. The
pigs of group 1 (PCV2-infected/LPC-vaccinated/CSFV-challenged)
and group 2 (PCV2-infected/CSFV-challenged) were inoculated with
PCV2 at 0 dpi. The pigs of group 1 and group 3 (LPC-vaccinated/
CSFV-challenged) were vaccinated with 1 dose of Lapinized
Philippines Coronel (LPC) vaccine at 12 dpi. The pigs of all four
groups were inoculated with CSFV (ALD strain) at 27 dpi. Data are
shown as mean ± SD.
Figure 3 The effect of porcine circovirus type 2 (PCV2) on the
classical swine fever virus (CSFV)-specific cell proliferation
reponse of peripheral blood mononuclear cells (PBMCs) in
various ex vivo treatments. The PBMCs were collected from pigs
that had been vaccinated with Lapinized Philippines Coronel (LPC)
vaccine twice, followed by challenge with wild-type CSFV (ALD) 6
weeks later. The PBMCs were pre-inoculated with 0.1, 0.05 or 0.01
MOI of PCV2, 0.1 MOI of UV-inactivated PCV2 or Con A at 5 μg/mL
followed by inoculation with 1 MOI of wild-type CSFV 18 h later.
This ex vivo CSFV-specific cell proliferation response was done in
triplicates and assayed 4 days after wild-type CSFV stimulation by
commercial kits as indicated in the material and methods. The
values are shown as mean ± SD of five different pigs.
a-dValues with
different superscripts indicate that the differences among groups
are statistically significant (P < 0.05).
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PCV2, humoral and cell-mediated immune responses
induced by LPC vaccine were both reduced. The level of
neutralizing antibody was not reduced, but the onset of
antibody production was sluggish; however, the CSFV-
specific CMI was significantly reduced. The incomplete
development of the immune response induced by LPC
vaccine, including both humoral and cell-mediated
immune responses, may have led to the temporal vire-
mia and viral sheddding in the saliva and feces in the
pigs following wild-type CSFV challenge.
The results of the ex vivo CSFV-specific PBMC prolif-
eration assay might explain the mechanism of PCV2-
derived reduction in the efficacy of LPC vaccine. Both live
and UV-inactivated PCV2 suppressed the CSFV-specific
PBMC proliferation. The cell population involved in the
CSFV-specific PBMC proliferation included CD4
+CD8
-
and CD4
-CD8
+ T lympocytes [22]. Significantly lower
numbers of CD4
-CD8
+CD25
+,C D 4
+CD8
-CD25
+,a n d
CD4
+CD8
+CD25
+ were noted in the pigs pre-inoculated
with PCV2. The PCV2-derived inhibition in the CSFV-
specific cell proliferative response of PBMCs was corre-
lated to the lymphocyte subset change after CSFV chal-
lenge. The number and function of T helper and cytotoxic
T lymphocytes against CSFV may also be depressed by
PCV2-derived inhibition. IL-10 and CpG motifs have been
demonstrated to be PCV2-associated immunosuppressing
factors in the PRV model [10,11]; however, neither factor
was illustrated in the inhibition on CSFV-specific PBMC
proliferation. The present study demonstrates that UV-
inactivated PCV2 could inhibit CSFV-specific PBMC pro-
liferation, and a similar inhibition pattern was also
observed in the PRV model [11]. The surface of PCV2 vir-
ion is composed of capsid protein, which binds to heparin
sulfate and chondroitin sulfate B glycosaminoglycan recep-
tors on the cell membrane during the infection process
[23]. It is speculated that the PCV2 capsid protein could
be a PCV2-associated immunosuppressing factor; this fac-
tor is therefore worth further study.
In contrast to pigs with simple CSFV challenge, pigs
pre-inoculated with PCV2 and then challenged with
CSFV showed significantly shortened survival times and
more severe clinical signs. The results suggest that
PCV2 may modulate the pig immune system leading
pigs to become more susceptible to CSFV infection. It is
known that CSFV is able to induce lymphocyte apopto-
sis and necrosis, directly or indirectly [16,24]. In addi-
tion, PCV2 induces lymphoid depletion in PMWS-
affected pigs [7,25] and reduces the function of macro-
phages such that the phagocytosis and microbicidal cap-
ability of alveolar macrophages are decreased [26]. How
PCV2 accelerates the severity of CSFV infection is
worth further study.
The present study has demonstrated that PCV2 could
decrease the efficacy of LPC vaccine. This information is
important, especially in the CSFV endemic areas using
attenuated vaccine for CSFV control and prevention.
Several measures should be considered to ameliorate the
problem caused by pandemic PCV2 infection such as
modification of the CSFV vaccination schedule or the
u s eo fav a c c i n eb o o s t e r .F i nally, whether the newly
developed CSFV subunit vaccines such as the E2 vaccine
are resistant to interference by PCV2 is another impor-
tant issue to be clarified.
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